Technologies
PDF


WARF: P07044US

Neuraminidase-Deficient Live Influenza Vaccine


INVENTORS -

Yoshihiro Kawaoka, Masato Hatta

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a modified influenza virus that could be used to produce safe but highly effective vaccines.
OVERVIEWInfluenza infects up to 20 percent of the world’s population every year, causing 500,000 deaths and costing tens of billions of dollars in medical expenses. Influenza A virus, which causes pandemics in humans, possesses two surface spike proteins called hemagglutinin (HA) and neuraminidase (NA) that are critical for infection and replication. Point mutations in these proteins allow the virus to evade the human immune response and provoke seasonal outbreaks.

Two general types of influenza vaccines are available: inactivated and live attenuated vaccines. Inactivated vaccines are safe but not always effective, especially among children and the elderly. In contrast, live attenuated influenza vaccines (LAIVs) are stronger and more efficacious. LAIVs also are more controversial because they involve living virus which is shed by the patient for several weeks. The virus contains mutations so that is can replicate but is not supposed to be virulent (i.e., cause flu). The safety of such vaccines varies.
THE INVENTIONUW–Madison researchers have developed a modified influenza virus that is infectious but completely avirulent. The virus can be used to prepare live attenuated virus stock for vaccines.

The virus was created by reverse genetics and lacks an NA gene segment necessary for functional sialidase activity. For this reason the seven-segment virus is innocuous but can still infect animals to induce the appropriate humoral and cellular immune responses.
BUSINESS OPPORTUNITY
  • Demand for influenza vaccines has been forecast to exceed 370 million doses and a market value of $3.7 billion.
APPLICATIONS
  • Generating live attenuated influenza vaccines
  • The NA-deficient virus can be used as a gene therapy vector.
KEY BENEFITS
  • Safe and highly efficacious
  • LAIVS are easier and more patient-friendly to administer.
  • NA-deficient virus combines several attractive features
    • High levels of attenuation
    • Easy to generate by reverse genetics
    • Biosafety, because the virus can’t revert to the wild-type phenotype
STAGE OF DEVELOPMENTPromising results have been demonstrated in mice.
Contact Information
For current licensing status, please contact Jennifer Gottwald at jennifer@warf.org or 608-960-9854.
The WARF Advantage

WARF: A Leader in Technology Transfer Since 1925
Since its founding as a private, nonprofit affiliate of the University of Wisconsin–Madison, WARF has provided patent and licensing services to UW–Madison and worked with commercial partners to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.

The University of Wisconsin and WARF –
A Single Location to Accelerate Translational Development of New Drugs

UW–Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities for research in the country, UW–Madison offers state-of-the-art facilities unmatched by most public universities.

These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW–Madison with a complete translational research facility; and the innovative, interdisciplinary Wisconsin Institutes for Discovery, home to the private, nonprofit Morgridge Institute for Research and its public twin, WID, part of the university's graduate school. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.